BiologicalDrug
CXCR2 Agonist MGTA-145 clinical trials
Also written MGTA-145.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
4 studies that test it; most in 2019 (1)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 1
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses CXCR2 Agonist MGTA-145 is read from its arms, and is right about nine times in ten.
Testing it · 4
- Study of MGTA-145 and Plerixafor in Patients With Sickle Cell DiseaseTerminatedPhase 2EnsomaNCT05445128Written as MGTA-145
- MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic MalignanciesTerminatedPhase 2EnsomaNCT04762875Written as MGTA-145
- Study Assessing PK and Safety of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal ImpairmentCompletedPhase 1EnsomaNCT04154670Written as MGTA-145
- MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple MyelomaCompletedPhase 2Surbhi Sidana, MDNCT04552743Written as MGTA-145